Fuller & Thaler Asset Management
INDV icon

Fuller & Thaler Asset Management’s Indivior Pharmaceuticals INDV Stock Holding History

Fuller & Thaler Asset Management’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$138M Sell
4,529,583
-1,841,951
-29% -$60.8M 0.46% 77
2025
Q4 		$229M Buy
6,371,534
+3,201,639
+101% +$97.8M 0.77% 22
2025
Q3 		$76.4M Buy
+3,169,895
New +$66.3M 0.26% 137

Other funds holding INDV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
OCM
Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fuller & Thaler Asset Management's INDV Position: Q1 2026 in Review

Fuller & Thaler Asset Management reduced its Indivior Pharmaceuticals (INDV) stake by 29% in Q1 2026, selling an estimated $60.8M and leaving 4,529,583 shares worth $138M. The position accounts for 0.46% of the portfolio, ranked #77.

Fuller & Thaler Asset Management first reported a position in INDV in Q3 2025 and has held it in 3 quarters since. The position peaked at $229M in Q4 2025. 289 funds tracked by Wall St. Rank hold INDV as of Q1 2026.

  • Fuller & Thaler Asset Management held 4,529,583 shares of Indivior Pharmaceuticals worth $138M as of Q1 2026.
  • Fuller & Thaler Asset Management sold 1,841,951 Indivior Pharmaceuticals shares in Q1 2026, an estimated $60.8M.
  • Indivior Pharmaceuticals made up 0.46% of Fuller & Thaler Asset Management's portfolio in Q1 2026, its #77 holding.
  • Fuller & Thaler Asset Management first reported a position in Indivior Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • Fuller & Thaler Asset Management's Indivior Pharmaceuticals position peaked at $229M in Q4 2025.
  • 289 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q1 2026.

Based on Fuller & Thaler Asset Management's 13F filing for Q1 2026, filed 14 May 2026.